|
See related Engerix-B vaccine information |
|
|
|
Manufacturer |
GlaxoSmithKline |
|
Distributor |
Hong Kong: Zuellig/Macau: Firma Chun Cheong |
|
Contents |
Adsorbed purified surface antigen of HBV |
|
Indications |
Active immunization against HBV.
Click to view Engerix-B detailed prescribing infomation |
|
Dosage |
Adult & childn ≥16 yr 20 mcg IM deltoid region. Neonate, infant & childn ≤15 yr 10 mcg IM anterolateral thigh given at elected date, 1 mth & 6 mth from date of 1st dose. Patients w/ renal insufficiency & undergoing haemodialysis ≥16 yr 4 doses of 40 mcg at elected date, 1, 2 & 6 mth from date of 1st dose. ≤15 yr & neonates Use either 0, 1, 2, & 12 mth or the 0, 1, 6 mth schedule.
Click to view Engerix-B detailed prescribing infomation |
|
Overdosage |
View Engerix-B overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Engerix-B detailed prescribing infomation |
|
Special Precautions |
Severe acute febrile illness. Pregnancy.
Click to view Engerix-B detailed prescribing infomation |
|
Adverse Drug Reactions |
Redness, pain, swelling at the inj site.
View ADR Monitoring Form |
|
Drug Interactions |
Immunosuppressives.
View more drug interactions with Engerix-B |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Engerix-B detailed prescribing infomation |
|
Storage |
View Engerix-B storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Engerix-B description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Engerix-B mechanism of action for pharmacodynamics and pharmacokinetics details. |
